Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 06:28pm CEST
   By Peter Loftus 
   Of  
 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -0.22% 62.37 Delayed Quote.9.53%
BRISTOL-MYERS SQUIBB COMPANY 0.15% 52.77 Delayed Quote.-14.02%
GILEAD SCIENCES -0.22% 67.38 Delayed Quote.-5.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
05/25ABBOTT LABORATORIES : Trademark Application for "PHOSPHAGEN" Filed by Abbott Lab..
AQ
05/25ABBOTT LABORATORIES : Trademark Application for "COMMITTED TO THE C.A.S.E." File..
AQ
05/25ABBOTT LABORATORIES : Patent Issued for Nutritional Supplement Powder (USPTO 996..
AQ
05/25ABBOTT LABORATORIES : Patent Issued for Cellular Analysis of Body Fluids (USPTO ..
AQ
05/24ABBOTT LABORATORIES : Investigational tendyne device for mitral valve replacemen..
AQ
05/24ABBOTT LABORATORIES : - newest generation of leading heart stent is now approved..
AQ
05/24ABBOTT LABORATORIES : Real-World Study Results Support Use of Abbott's AMPLATZER..
PU
05/23ABBOTT LABORATORIES : Newest Generation of Leading Heart Stent is Now Approved i..
PR
05/23ABBOTT : 's Investigational Tendyne™ Device for Mitral Valve Replacement D..
PR
05/23ABBOTT LABORATORIES : $96,439 Federal Contract Awarded to Abbott Laboratories
AQ
More news
News from SeekingAlpha
05/23Abbott's Tendyne mitral valve shows positive effect in global study 
05/22Abbott's stent guide improved outcomes in long-term study 
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/16THE 30+1 PORTFOLIO : An Average Investor's Reasoning For Buying A Stock 
05/03My Dividend Growth Portfolio - 42 Holdings, 4 Buys 
Financials ($)
Sales 2018 30 950 M
EBIT 2018 6 458 M
Net income 2018 2 536 M
Debt 2018 15 152 M
Yield 2018 1,79%
P/E ratio 2018 47,86
P/E ratio 2019 33,96
EV / Sales 2018 4,02x
EV / Sales 2019 3,71x
Capitalization 109 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 68,5 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES9.53%109 346
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970